Table 1.

Parkinsons’s disease patients-demographic and clinical characteristics

Sex	Age	Disease duration	More affected side	H&Y	UPDRS off	UPDRS on	MMSE	MAS off		MAS on		BDI off		BDI on		TPQ-ns	TPQ-ha	TPQ-rd	Drugs	LED (mg)
M	50	8	R	3	28	15	30	15	11		5		7		4		17	9	Rop	120
M	62	3	L	3	29	14	29	8	9		13		13		17		15	17	L-Dopa Ras	400
F	69	3	L	3	37	32	30	22	23		14		13		8		10	16	Rop L-Dopa	460
M	57	2	R	2	20	14	29	29	35		19		15		19		11	8	L-Dopa	300
M	62	5	R	3	49	20	30	16	5		10		3		17		18	18	Rop L-Dopa	620
F	57	3	L	2	15	4	30	7	5		4		7		13		8	12	Rop	200
M	70	8	R	2	26	15	30	17	17		10		19		19		18	17	L-Dopa	375
M	62	5	L	2	28	10	30	12	13		16		17		17		24	15	Pram L-Dopa	400
F	56	6	L	3	30	17	29	5	6		14		12		13		8	12	Pram L-Dopa	400
M	70	5	R	3	42	12	28	10	8		6		6		12		7	15	L-Dopa	375
F	68	6	R	3	40	9	30	16	12		5		4		16		8	15	L-Dopa	460
Average	62.1	4.9		2.6	31.3	14.7	29.5	14.7	13.7		10.1		10		14.1		13.1	14		373.7
SEM	2.0	0.6		0.15	0.15	2.15	0.2	2	2.6		1.5		1.6		1.4		1.7	1		40

M male, F female, H&Y Hoehn and Yahr stage, Motor section of UPDRS United Parkinson Disease Rating Scale (OFF, off medication; ON, on medication), MMSE Mini Mental State Examination, MAS Marin Apathy Scale, BDI Beck Depression Inventory, TPQ Tridimensional Personality Questionnaire, ns novelty seeking, ha harm avoidance, rd reward dependence, Ras rasegeline, Rop ropinirole, Pram pramipexole, LED L-Dopa Equivalent Dose in milligrams, SEM Standard Error of the Mean